The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Agovirin     [(8S,9S,10R,13S,14S,17S)- 10,13-dimethyl-3...

Synonyms: Androlon, Masenate, Synerone, Testodet, Testogen, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Agovirin


Psychiatry related information on Agovirin


High impact information on Agovirin


Chemical compound and disease context of Agovirin


Biological context of Agovirin

  • The term "partial androgen insensitivity syndrome" describes this condition more accurately than a term based on clinical phenotype [19].
  • The low amount of androgen receptor and the combination of high serum gonadotropins and plasma testosterone production rates suggest that the defective spermatogenesis in these infertile men was the consequence of androgen insensitivity [20].
  • Our results suggest that AR amplification emerges during androgen deprivation therapy by facilitating tumour cell growth in low androgen concentrations [21].
  • The 5' LTR of this element corresponds to the previously characterized hormone-responsive enhancer associated with Slp regulation, leading to the conclusion that the provirus has conferred androgen response on the adjacent Slp gene [22].
  • Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer [23].

Anatomical context of Agovirin

  • One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line [24].
  • Dihydrotestosterone binding studies in skin fibroblasts demonstrated two genetic variants similar to those reported in complete androgen insensitivity syndrome [19].
  • Dependent cells form tumors preferentially in male animals and dependent cell cytosols contain significant amounts (approximately 300 femtomoles per mg protein) of a specific androgen-binding macromolecule [3].
  • BACKGROUND: Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations [25].
  • The source of the excess androgen may be either the ovaries or the adrenal glands, and distinguishing between these sources may be difficult [26].

Associations of Agovirin with other chemical compounds


Gene context of Agovirin


Analytical, diagnostic and therapeutic context of Agovirin


  1. The current state of hormonal therapy for prostate cancer. Hellerstedt, B.A., Pienta, K.J. CA: a cancer journal for clinicians. (2002) [Pubmed]
  2. Detection of functional ovarian hyperandrogenism in women with androgen excess. Ehrmann, D.A., Rosenfield, R.L., Barnes, R.B., Brigell, D.F., Sheikh, Z. N. Engl. J. Med. (1992) [Pubmed]
  3. Development of methods for the quantitative in vitro analysis of androgen-dependent and autonomous Shionogi carcinoma 115 cells. Stanley, E.R., Palmer, R.E., Sohn, U. Cell (1977) [Pubmed]
  4. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Wooster, R., Mangion, J., Eeles, R., Smith, S., Dowsett, M., Averill, D., Barrett-Lee, P., Easton, D.F., Ponder, B.A., Stratton, M.R. Nat. Genet. (1992) [Pubmed]
  5. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mulaikal, R.M., Migeon, C.J., Rock, J.A. N. Engl. J. Med. (1987) [Pubmed]
  6. Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. Gordon, G.G., Altman, K., Southren, A.L., Rubin, E., Lieber, C.S. N. Engl. J. Med. (1976) [Pubmed]
  7. Androgen receptors exist throughout the 'critical period' of brain sexual differentiation. Vito, C.C., Wieland, S.J., Fox, T.O. Nature (1979) [Pubmed]
  8. Pedophilia. Fagan, P.J., Wise, T.N., Schmidt, C.W., Berlin, F.S. JAMA (2002) [Pubmed]
  9. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Looijenga, L.H., de Leeuw, H., van Oorschot, M., van Gurp, R.J., Stoop, H., Gillis, A.J., de Gouveia Brazao, C.A., Weber, R.F., Kirkels, W.J., van Dijk, T., von Lindern, M., Valk, P., Lajos, G., Olah, E., Nesland, J.M., Fosså, S.D., Oosterhuis, J.W. Cancer Res. (2003) [Pubmed]
  10. Exogenous androgens in postmenopausal women. Sands, R., Studd, J. Am. J. Med. (1995) [Pubmed]
  11. Advances in prostate cancer chemotherapy: a new era begins. Pienta, K.J., Smith, D.C. CA: a cancer journal for clinicians. (2005) [Pubmed]
  12. Integrative molecular concept modeling of prostate cancer progression. Tomlins, S.A., Mehra, R., Rhodes, D.R., Cao, X., Wang, L., Dhanasekaran, S.M., Kalyana-Sundaram, S., Wei, J.T., Rubin, M.A., Pienta, K.J., Shah, R.B., Chinnaiyan, A.M. Nat. Genet. (2007) [Pubmed]
  13. Role of endocytosis in cellular uptake of sex steroids. Hammes, A., Andreassen, T.K., Spoelgen, R., Raila, J., Hubner, N., Schulz, H., Metzger, J., Schweigert, F.J., Luppa, P.B., Nykjaer, A., Willnow, T.E. Cell (2005) [Pubmed]
  14. Treatment of familial male precocious puberty with spironolactone and testolactone. Laue, L., Kenigsberg, D., Pescovitz, O.H., Hench, K.D., Barnes, K.M., Loriaux, D.L., Cutler, G.B. N. Engl. J. Med. (1989) [Pubmed]
  15. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. Peters, C.A., Walsh, P.C. N. Engl. J. Med. (1987) [Pubmed]
  16. Male hypogonadism with gynecomastia caused by late-onset deficiency of testicular 17-ketosteroid reductase. Castro-Magana, M., Angulo, M., Uy, J. N. Engl. J. Med. (1993) [Pubmed]
  17. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. Holland, F.J., Fishman, L., Bailey, J.D., Fazekas, A.T. N. Engl. J. Med. (1985) [Pubmed]
  18. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., Kantoff, P.W., Finkelstein, J.S. N. Engl. J. Med. (2001) [Pubmed]
  19. Partial androgen insensitivity: the Reifenstein syndrome revisited. Amrhein, J.A., Klingensmith, G.J., Walsh, P.C., McKusick, V.A., Migeon, C.J. N. Engl. J. Med. (1977) [Pubmed]
  20. Androgen insensitivity as a cause of infertility in otherwise normal men. Aiman, J., Griffin, J.E., Gazak, J.M., Wilson, J.D., MacDonald, P.C. N. Engl. J. Med. (1979) [Pubmed]
  21. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., Kallioniemi, O.P. Nat. Genet. (1995) [Pubmed]
  22. An ancient provirus has imposed androgen regulation on the adjacent mouse sex-limited protein gene. Stavenhagen, J.B., Robins, D.M. Cell (1988) [Pubmed]
  23. Megestrol acetate for the prevention of hot flashes. Loprinzi, C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, R.A., Dose, A.M., Fischer, T., Johnson, C., Klatt, N.E. N. Engl. J. Med. (1994) [Pubmed]
  24. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N., Balk, S.P. N. Engl. J. Med. (1995) [Pubmed]
  25. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor, H., Williford, W.O., Barry, M.J., Brawer, M.K., Dixon, C.M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., Padley, R.J. N. Engl. J. Med. (1996) [Pubmed]
  26. ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. Siegel, S.F., Finegold, D.N., Lanes, R., Lee, P.A. N. Engl. J. Med. (1990) [Pubmed]
  27. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1. Speiser, P.W., New, M.I., White, P.C. N. Engl. J. Med. (1988) [Pubmed]
  28. The role of growth hormone in alpha 2u globulin synthesis: a reexamination. Lynch, K.R., Dolan, K.P., Nakhasi, H.L., Unterman, R., Feigelson, P. Cell (1982) [Pubmed]
  29. Androgen-regulated expression of a cloned rat prostatic c3 gene transfected into mouse mammary tumor cells. Page, M.J., Parker, M.G. Cell (1983) [Pubmed]
  30. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. Nestler, J.E., Jakubowicz, D.J., Reamer, P., Gunn, R.D., Allan, G. N. Engl. J. Med. (1999) [Pubmed]
  31. Disorders of steroid 11 beta-hydroxylase isozymes. White, P.C., Curnow, K.M., Pascoe, L. Endocr. Rev. (1994) [Pubmed]
  32. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Lubahn, D.B., Joseph, D.R., Sullivan, P.M., Willard, H.F., French, F.S., Wilson, E.M. Science (1988) [Pubmed]
  33. Hormonal and cellular regulation of Sertoli cell anti-Müllerian hormone production in the postnatal mouse. Al-Attar, L., Noël, K., Dutertre, M., Belville, C., Forest, M.G., Burgoyne, P.S., Josso, N., Rey, R. J. Clin. Invest. (1997) [Pubmed]
  34. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Agus, D.B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D.W., Scher, H.I. J. Natl. Cancer Inst. (1999) [Pubmed]
  35. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. Sumitomo, M., Shen, R., Walburg, M., Dai, J., Geng, Y., Navarro, D., Boileau, G., Papandreou, C.N., Giancotti, F.G., Knudsen, B., Nanus, D.M. J. Clin. Invest. (2000) [Pubmed]
  36. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger, M.A., Blumenstein, B.A., Crawford, E.D., Miller, G., McLeod, D.G., Loehrer, P.J., Wilding, G., Sears, K., Culkin, D.J., Thompson, I.M., Bueschen, A.J., Lowe, B.A. N. Engl. J. Med. (1998) [Pubmed]
  37. A comparison of androgens for anemia in patients on hemodialysis. Neff, M.S., Goldberg, J., Slifkin, R.F., Eiser, A.R., Calamia, V., Kaplan, M., Baez, A., Gupta, S., Mattoo, N. N. Engl. J. Med. (1981) [Pubmed]
  38. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. Gelfand, J.A., Sherins, R.J., Alling, D.W., Frank, M.M. N. Engl. J. Med. (1976) [Pubmed]
  39. Androgen receptors in the brain: what are we measuring? Sheridan, P.J. Endocr. Rev. (1983) [Pubmed]
  40. Immunoassay of androgen binding protein in blood: a new approach for study of the seminiferous tubule. Gunsalus, G.L., Musto, N.A., Bardin, W. Science (1978) [Pubmed]
WikiGenes - Universities